Enjoy complimentary customisation on priority with our Enterprise License!
The Human Vaccine Market size is estimated to grow by USD 29.1 billion at a CAGR of 9.49% between 2023 and 2028.
There has been a rise in public immunization programs funded by the governments of various countries which is significantly contributing to the market growth. For example, UIP was launched by the Government of India to provide vaccines against tuberculosis, polio, and other diseases for all Indian children Moreover, UIP provided vaccines that included BCG for TB, DPT for diphtheria, pertussis, and tetanus, oral polio vaccine (OPV), and vaccines for measles. Hence, such factors are positively impacting the market.
Technavio has segmented the market into Route Of Administration, End-user, and Geography
It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historical data from 2018 - 2022, besides analyzing the current market scenario.
To learn more about this report, Request Free Sample
The intramuscular segment is estimated to witness significant growth during the forecast period. One of the main factors for the growth of this segment is the benefits of intramuscular administration. In addition, it is efficient and safe in inducing an immune response compared with the oral ROA. Furthermore, oral vaccination is associated with some risk factors, such as a rich microbiome and enteropathy.
Get a glance at the market contribution of various segments Download PDF Sample
The intramuscular segment was the largest segment and was valued at USD 16.37 billion in 2018. Moreover, most of the vaccines are delivered parenterally, mainly intramuscularly, in infants and children. In addition, several pipeline vaccine products are being evaluated in the intramuscular ROA because of their advantages over the oral ROA. Furthermore, the market has witnessed the development and approval of an intramuscular vaccine for COVID-19, which is positively impacting the market. For instance, the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, is an mRNA vaccine encoded with a P2 mutant spike protein and formulated as an RNA lipid nanoparticle of nucleoside-modified mRNA. BNT162b2 elicits a blunted innate immune sensor-activating capacity and thus augments antigen expression. Hence, such factors are fuelling the growth of this segment which in turn drives the market growth during the forecast period.
The pediatric age group is of high significance in the global vaccine research market due to the sustained emphasis on the creation and delivery of vaccines for children. The health of children across the world has been greatly improved, and different infectious childhood diseases have been eradicated due to the pediatric vaccination programs carried out worldwide. The market environment for pediatric vaccinations is characterized by rising R&D spending, stringent regulatory standards, and rising demand for vaccines that are both safe and efficacious for children. For instance, vaccines against diseases such as measles, mumps, rubella (MMR) and diphtheria, tetanus, and pertussis (DTaP) are widely administered to children across the world and have been the subject of substantial research globally. Such factors will drive the growth of the global human vaccine market during the forecast period.
In the global human vaccine market, vaccines targeted at the adult age group are experiencing tremendous expansion and development. A growing emphasis is being placed on creating vaccines that are specifically aimed at adults, primarily due to the aging population and rising awareness of diseases that can be prevented by vaccination. In the adult vaccine industry, vaccines for influenza, pneumococcal disease, and shingles have become increasingly popular. Further more as new vaccines are discovered, and vaccination rates increase globally, adult vaccine research is anticipated to continue growing and drive the growth of the global human vaccine market during the forecast period.
For more insights about the market share of various regions Download PDF Sample now!
North America is estimated to contribute 39% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. One of the main factors for the growth of the market in North America is due to the increasing number of immunization programs and the strong prevalence of infectious diseases such as influenza, hepatitis A, hepatitis B, HIV, measles, malaria, tuberculosis, and non-infectious diseases such as cancer.
In addition, the prevalence of several infectious and non-infectious diseases has been increasing at a significant rate in the developed countries of the region. For example, in the US, the prevalence of influenza rises every year in November and remains high for several weeks, from January to February each year. Furthermore, some of the prominent vaccine players in North America include GlaxoSmithKline, Pfizer, Merck, and Johnson & Johnson. Hence, such factors are driving the market growth in North America during the forecast period.
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:
Astellas Pharma Inc: The company offers human vaccines such as Acam2000, BAT, BioThrax and many more.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
There are multiple factors influencing market growth. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges.
One of the key factors driving the human vaccine market growth is the need for novel vaccines for chronic infections. There is an increasing need for novel vaccines to prevent several emerging and re-emerging infectious diseases. As a result, government and non-government organizations worldwide are increasing the research on novel vaccines for various infections, including HIV, Staphylococcus aureus, C. difficile, influenza, and respiratory syncytial virus. In addition, with the use of new and traditional technologies, many vaccine candidates have been studied in clinical research.
Moreover, there are numerous vaccine targets, including Group A streptococcal meningitis, Chlamydia trachomatis, pneumococcal, universal influenza, and C. difficile across the world. In addition, funding for vaccine development comes from several organizations, such as Global Health and US Federal Funding for translational medicines. Hence, such factors are positively impacting the market. Therefore, it is expected to drive the market growth during the forecast period.
A key factor shaping the human vaccine market growth is the development in nano-particle vaccines. The emergence of various infectious and other diseases has become a serious threat to the health of millions of people worldwide. In addition, some vaccines were developed by researchers from protein subunits and killed pathogens, whereas several vaccines were based on live attenuated organisms. However, these vaccines have the risk of regaining their pathogenicity under certain immunocompromised conditions.
Therefore, to overcome this challenge, the development of effective vaccines in combination with adequate delivery systems is important to obtain the desired humoral and cell-mediated immunity against specific diseases. Furthermore, over the years, the development of nanoparticle-based vaccines has been gaining traction for improving immunization strategies, vaccine efficacy, and targeted delivery to achieve desired immune responses. Hence, such factors are driving the market growth during the forecast period.
Concerns about the safety of vaccines are one of the key challenges hindering the human vaccine market growth. There are numerous risks associated with the vaccine such as the increased risk of certain diseases such as autism and the Guillain-Barre syndrome. In addition, studies by the CDC indicate that vaccination may not be related to these diseases.
Moreover, the common side effects of vaccination include injection site reactions, mild fever, fatigue, pain, and fainting. In addition, some vaccines may show serious effects. For example, the dengue vaccine has serious effects, including the occurrence of severe hemorrhagic dengue fever. Hence, such factors are negatively impacting the market. Therefore, it is expected to hinder the market growth during the forecast period.
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Human Vaccine Market Customer Landscape
The human vaccine market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2018 to 2028.
|
Human Vaccine Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
166 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 9.49% |
|
Market Growth 2024-2028 |
USD 29.1 billion |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
8.56 |
|
Regional analysis |
North America, Europe, Asia, and the Rest of the World (ROW) |
|
Performing market contribution |
North America at 39% |
|
Key countries |
US, Canada, Germany, UK, and China |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
Astellas Pharma Inc., AstraZeneca Plc, Bavarian Nordic AS, Bharat Biotech Ltd., BioNTech SE, CanSino Biologics Inc., CSL Ltd., Daiichi Sankyo Co. Ltd., Emergent BioSolutions Inc., GlaxoSmithKline Plc, Gradalis Inc., Inovio Pharmaceuticals Inc., Johnson and Johnson, Merck and Co. Inc., Mitsubishi Chemical Group Corp., Moderna Inc., Novavax Inc., Pfizer Inc., Serum Institute of India Pvt. Ltd., and Sanofi SA |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Download Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Route of Administration
7 Market Segmentation by End-user
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
Get the report (PDF) sent to your email within minutes.